chr17-31259038-C-G
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_001042492.3(NF1):c.4339C>G(p.Gln1447Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q1447R) has been classified as Pathogenic.
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 28
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
In the published literature, this variant has been reported in individuals with Neurofibromatosis type 1 (NF1) or suspected NF1 (PMIDs: 23913538 (2013), 31370276 (2019), and 33443663 (2021)). In addition, this variant has been reported to occur de novo in a symptomatic individual. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is disease causing and damaging. Therefore, the variant is classified as pathogenic. -
Observed in individuals with NF1-related features referred for genetic testing at GeneDx and in published literature (PMID: 23913538, 31370276, 33443663); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25486365, 22807134, 26969325, 30104198, 23913538, 31370276, 33443663) -
Neurofibromatosis, type 1 Pathogenic:1
This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 1426 of the NF1 protein (p.Gln1426Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with NF1 and clinical features of neurofibromatosis type 1 (NF1) (PMID: 23913538; Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 639280). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NF1 protein function with a positive predictive value of 95%. This variant disrupts the p.Gln1426 amino acid residue in NF1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26969325; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
The p.Q1426E pathogenic mutation (also known as c.4276C>G), located in coding exon 32 of the NF1 gene, results from a C to G substitution at nucleotide position 4276. The glutamine at codon 1426 is replaced by glutamic acid, an amino acid with highly similar properties. This alteration has been identified in multiple individuals with a clinical diagnosis of neurofibromatosis type 1 (NF1) (Ambry internal data; Sabbagh A et al. Hum Mutat, 2013 Nov;34:1510-8; Giugliano T et al. Genes (Basel), 2019 07;10:). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). Another alteration at the same codon, p.Q1426H (c.4278G>C), has been identified in an individual with a clinical diagnosis of NF1 (Giugliano T et al. Genes (Basel), 2019 07;10:). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at